Certara, Inc. (CERT)

NASDAQ: CERT · IEX Real-Time Price · USD
23.87
-0.86 (-3.48%)
Jan 27, 2022 4:00 PM EST - Market closed
Market Cap3.81B
Revenue (ttm)275.40M
Net Income (ttm)-58.01M
Shares Out159.68M
EPS (ttm)-0.40
PE Ration/a
Forward PE111.11
Dividendn/a
Ex-Dividend Daten/a
Volume386,165
Open25.12
Previous Close24.73
Day's Range23.79 - 25.48
52-Week Range23.75 - 45.48
Betan/a
AnalystsBuy
Price Target40.60 (+70.1%)
Earnings Daten/a

About CERT

Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, em...

IndustryBiotechnology
IPO DateDec 11, 2020
Employees846
Stock ExchangeNASDAQ
Ticker SymbolCERT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for Certara stock is "Buy." The 12-month stock price forecast is 40.60, which is an increase of 70.09% from the latest price.

Price Target
$40.60
(70.09% upside)
Analyst Consensus: Buy

News

Can Certara, Inc. (CERT) Run Higher on Rising Earnings Estimates?

Certara, Inc. (CERT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

3 weeks ago - Zacks Investment Research

Can Certara, Inc. (CERT) Climb 35% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Certara, Inc. (CERT). While the effectiveness of this highly sought-after metric is questionable, the po...

3 weeks ago - Zacks Investment Research

Certara Announces FDA Renewal and Expansion of Certara's Biosimulation Software for Reviewing Regulatory Submissions

FDA holds more than 400 Simcyp™ and Phoenix™ software licenses across 12 divisions and offices FDA holds more than 400 Simcyp™ and Phoenix™ software licenses across 12 divisions and offices

1 month ago - GlobeNewsWire

Certara Announces Release of Pinnacle 21 Enterprise Software

New metrics and analytics capabilities enable informed decision making for biopharmaceutical clients New metrics and analytics capabilities enable informed decision making for biopharmaceutical clients

1 month ago - GlobeNewsWire

Certara to Host Investor Day on December 15, 2021

PRINCETON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, will host an Investor Day on Wednesday, December 15, 2021 from 3:00 PM to 6:00 PM ET in...

1 month ago - GlobeNewsWire

Certara Announces Release of Simcyp™ Simulator Version 21, Expanding Capabilities to Align with Recent Regulatory Gui...

Simcyp Simulator has been used to inform more than 250 label claims for 85+ novel drugs Simcyp Simulator has been used to inform more than 250 label claims for 85+ novel drugs

1 month ago - GlobeNewsWire

Certara Announces Update of D360™ Scientific Informatics Software

New capabilities increase efficiency in analyzing and developing small molecules and biologic drugs New capabilities increase efficiency in analyzing and developing small molecules and biologic drugs

1 month ago - GlobeNewsWire

Certara Announces Closing of Public Offering of Common Stock

PRINCETON, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the closing of its underwritten public offering of 10,000,000 shares of...

2 months ago - GlobeNewsWire

Certara Announces Pricing of Public Offering of Common Stock

PRINCETON, N.J., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the pricing of its underwritten public offering of 10 million shares of...

2 months ago - GlobeNewsWire

Certara Announces Proposed Public Offering of Common Stock

PRINCETON, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a proposed underwritten public offering by certain selling stockholders...

2 months ago - GlobeNewsWire

Certara Reports Third Quarter 2021 Financial Results

Raises full year 2021 guidance, reflecting strong revenue growth and the acquisition of Pinnacle 21 Raises full year 2021 guidance, reflecting strong revenue growth and the acquisition of Pinnacle 21

2 months ago - GlobeNewsWire

Certara Appoints James E. Cashman III as Chairman of Board of Directors

High-tech CEO with decades of experience supports continued innovation and growth High-tech CEO with decades of experience supports continued innovation and growth

2 months ago - GlobeNewsWire

Certara to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

PRINCETON, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that William F. Feehery, Chief Executive Officer, and Andrew Schemick, ...

2 months ago - GlobeNewsWire

Pinnacle 21 Awarded FDA Contract for 5 Years for Software and Services

Pinnacle 21 Enterprise software expedites regulatory review of all study submission data Pinnacle 21 Enterprise software expedites regulatory review of all study submission data

2 months ago - GlobeNewsWire

Certara's Simcyp™ COVID-19 Vaccine Model Wins R&D 100 Award

Biosimulation tool to conduct ‘what-if' scenarios with virtual patients recognized in Software/Services category Biosimulation tool to conduct ‘what-if' scenarios with virtual patients recognized in Sof...

3 months ago - GlobeNewsWire

Certara to Report Third Quarter 2021 Financial Results on November 9th, 2021

PRINCETON, N.J., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2021 af...

3 months ago - GlobeNewsWire

Certara Appoints Patrick F. Smith to President of Integrated Drug Development

PRINCETON, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Patrick F. Smith, Pharm.D. as president of Integrate...

3 months ago - GlobeNewsWire

Certara Appoints Drayton T. Virkler as Chief Commercial Officer

Experienced commercial leader brings 20 years of experience in pharma Experienced commercial leader brings 20 years of experience in pharma

3 months ago - GlobeNewsWire

Certara Completes Acquisition of Pinnacle 21

Complementary technologies accelerate and help assure success in the drug development process Complementary technologies accelerate and help assure success in the drug development process

3 months ago - GlobeNewsWire

Certara Launches New Synchrogenix™ Writer Software to Accelerate the Regulatory Submission Process

Cloud-based and validated regulatory software automates and advances quality of patient narratives Cloud-based and validated regulatory software automates and advances quality of patient narratives

3 months ago - GlobeNewsWire

Certara Announces New Clinical Science Group and Adds Senior Scientific Experts

Multi-Disciplinary Expansion and New Appointments Grow Capacity and Capabilities Multi-Disciplinary Expansion and New Appointments Grow Capacity and Capabilities

4 months ago - GlobeNewsWire

Certara Awarded FDA Grant to Further Advance Virtual Bioequivalence Assessments of Generic Medicines Using Biosimulation

Represents Fourth FDA Grant for Simcyp MechDermA™ Model for Virtual Bioequivalence Represents Fourth FDA Grant for Simcyp MechDermA™ Model for Virtual Bioequivalence

4 months ago - GlobeNewsWire

Certara Announces Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Pur...

PRINCETON, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it closed its public offering of 23,000,000 shares of common stoc...

4 months ago - GlobeNewsWire

Certara Stock Under Pressure On Equity Raise Of $140M At 12% Discount

Certara Inc (NASDAQ: CERT) has priced its previously announced underwritten public offering of 4.5 million shares at $31.00 per share for gross proceeds of $139.5 million. The offer price represents a d...

4 months ago - Benzinga

Certara to Participate in Upcoming Investor Conferences

PRINCETON, N.J., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in a fireside chat at the foll...

4 months ago - GlobeNewsWire